TriangleSacituzumab govitecan (NCT06161532)
Sacituzumab govitecan trial for Small Cell Carcinoma of the Bladder (NCT06161532). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with eligible unresectable or metastatic non-prostate genitourinary cancers. High-grade neuroendocrine cancers require previous platinum chemotherapy; other eligible types may be untreated.
The idea: deliver chemotherapy to Trop2-bearing cells using sacituzumab govitecan. Patients previously given checkpoint immunotherapy, or unable to receive it, get this drug alone. Eligible patients without previous checkpoint treatment also receive atezolizumab, which blocks PD-L1. Infusions follow 21-day cycles. Researchers assess response; tissue is required.
This phase 2 study plans 60 patients. Andrea Apolo leads at NIH in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.